Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Thursday,Benzinga reports. The firm issued an overweight rating and a $135.00 price target on the stock.

Several other equities research analysts also recently weighed in on the stock. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $63.00 to $123.00 in a research note on Tuesday, March 10th. HC Wainwright upped their price target on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Robert W. Baird raised their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $117.30.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $80.00 on Thursday. The company has a market capitalization of $3.56 billion, a PE ratio of -19.51 and a beta of 1.56. The company has a 50-day simple moving average of $55.86 and a two-hundred day simple moving average of $44.08. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 33,830 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $10,016,587.82. The SEC filing for this sale provides additional information. Insiders sold 200,430 shares of company stock worth $16,332,702 over the last three months. Company insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the second quarter valued at approximately $27,000. Parkside Financial Bank & Trust boosted its position in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.